A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

Código QR

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

David A Godfrey1, Lee S Peplinski2, Jeanette A Stewart3, William C Stewart31Glaucoma Associates of Texas, Dallas, TX, USA; 2Kentuckiana Institute for Eye Research, Louisville, KY, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas, TX, USAPurpose: To determine the short-term comfort after a sing...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	David A Godfrey, Lee S Peplinski, Jeanette A Stewart, William C Stewart
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/9c415153b98b461bb0fe2a32383eb58b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Michael J Miyashiro, et al.
Publicado: (2010)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2012)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Douglas J Rhee, et al.
Publicado: (2008)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado AS, et al.
Publicado: (2011)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue K, et al.
Publicado: (2012)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Kanamoto T, et al.
Publicado: (2012)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis V, et al.
Publicado: (2018)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
por: Dubiner HB, et al.
Publicado: (2012)

Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy
por: Costa VP, et al.
Publicado: (2012)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe N, et al.
Publicado: (2020)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell JH, et al.
Publicado: (2014)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Yelda Buyru &Ouml;zkurt, et al.
Publicado: (2009)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
por: Inoue K, et al.
Publicado: (2012)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue K, et al.
Publicado: (2014)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
por: Inoue K, et al.
Publicado: (2012)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Gregory Katz, et al.
Publicado: (2010)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
por: Brant Fernandes RA, et al.
Publicado: (2019)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: J Charles Henry, et al.
Publicado: (2008)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Sophia K Mirza, et al.
Publicado: (2010)

Impacto sobre el tamaño de las muestras en estudios nacionales si cambiara el nivel de significación estadística de α= 0,05 a α = 0,005
por: Villarroel del Pino,Luis
Publicado: (2021)

Sodium Hypochlorite 0.005% Versus Placebo in the Treatment of Mild to Moderate Acne: A Double-Blind Randomized Controlled Trial
por: Azadeh Dorostkar, et al.
Publicado: (2021)

Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies
por: Arthur B Epstein, et al.
Publicado: (2009)

Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi T, et al.
Publicado: (2017)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue K, et al.
Publicado: (2012)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural E, et al.
Publicado: (2011)

Distinct domain switching in Nd0.05Ce0.95CoIn5 at low and high fields
por: D. G. Mazzone, et al.
Publicado: (2018)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

LiNi0.8Co0.15Al0.05O2: Enhanced Electrochemical Performance From Reduced Cationic Disordering in Li Slab
por: Peng Xiao, et al.
Publicado: (2017)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

The Bayes Factor, a Suitable Complement beyond Values of p<0.05 in Nursing Research and Education
por: Cristian Antony Ramos-Vera
Publicado: (2021)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo J, et al.
Publicado: (2016)

PERSIANN-CCS-CDR, a 3-hourly 0.04° global precipitation climate data record for heavy precipitation studies
por: Mojtaba Sadeghi, et al.
Publicado: (2021)

Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
por: Palacio-Pastrana C, et al.
Publicado: (2020)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher KG, et al.
Publicado: (2016)

Difluprednate ophthalmic emulsion 0.05% (Durezol&reg;) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Stephen Smith, et al.
Publicado: (2010)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)